{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:47:28Z","timestamp":1788648448806,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40256-021-00489-3","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T01:02:26Z","timestamp":1627261346000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery"],"prefix":"10.1007","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct01661101","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-7621","authenticated-orcid":false,"given":"Andre","family":"Lamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-6103","authenticated-orcid":false,"given":"Wesley","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajibul","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-1123","authenticated-orcid":false,"given":"Wojciech","family":"Szczeklik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Biccard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Duceppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Graza","family":"Franzosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadeesh K.","family":"Srinathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Meyhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Parlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"Devereaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"489_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/ALN.0000000000000113","volume":"120","author":"F Botto","year":"2014","unstructured":"Botto F, Alonso-Coello P, Chan MTV, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology. 2014;120:564\u201378.","journal-title":"Anesthesiology"},{"key":"489_CR2","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1001\/jama.2017.4360","volume":"317","author":"PJ Devereaux","year":"2017","unstructured":"Devereaux PJ, Biccard BM, Sigamani A, et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2017;317:1642\u201351.","journal-title":"JAMA"},{"key":"489_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1097\/ALN.0b013e31820ad503","volume":"114","author":"M Levy","year":"2011","unstructured":"Levy M, Heels-Ansdell D, Hiralal R, et al. Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis. Anesthesiology. 2011;114:796\u2013806.","journal-title":"Anesthesiology"},{"key":"489_CR4","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/S0140-6736(18)30832-8","volume":"391","author":"PJ Devereaux","year":"2018","unstructured":"Devereaux PJ, Duceppe E, Guyatt G, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018;391:2325\u201334.","journal-title":"Lancet"},{"key":"489_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cjca.2018.01.020","volume":"34","author":"E Duceppe","year":"2018","unstructured":"Duceppe E, Yusuf S, Tandon V, et al. Design of a randomized placebo-controlled trial to assess dabigatran and omeprazole in patients with myocardial injury after noncardiac surgery (MANAGE). Can J Cardiol. 2018;34:295\u2013302.","journal-title":"Can J Cardiol"},{"key":"489_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cjca.2011.08.112","volume":"28","author":"A Lamy","year":"2012","unstructured":"Lamy A, Tong W, Gao P, et al. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. Can J Cardiol. 2012;28:95\u2013101.","journal-title":"Can J Cardiol"},{"key":"489_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jdiacomp.2014.02.012","volume":"28","author":"A Lamy","year":"2014","unstructured":"Lamy A, Tong W, Jung H, et al. Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. J Diabetes Complicat. 2014;28:553\u20138.","journal-title":"J Diabetes Complicat"},{"key":"489_CR8","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.athoracsur.2014.06.046","volume":"98","author":"A Lamy","year":"2014","unstructured":"Lamy A, Tong W, Devereaux PJ, et al. The cost implications of off-pump versus on-pump coronary artery bypass graft surgery at one year. Ann Thorac Surg. 2014;98:1620\u20135.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"489_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/ehjqcco\/qcz001","volume":"5","author":"A Lamy","year":"2019","unstructured":"Lamy A, Lonn E, Tong W, et al. The cost implication of primary prevention in the HOPE 3 trial. Eur Heart J Qual Care Clin Outcomes. 2019;5(3):266\u201371.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"489_CR10","unstructured":"Anon. Formulary search\u2014search results. https:\/\/www.formulary.health.gov.on.ca\/formulary\/results.xhtml?q=dabigatran&type=1. Accessed 23 Mar 2020"},{"key":"489_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/135581969800300410","volume":"3","author":"A Briggs","year":"1998","unstructured":"Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy. 1998;3:233\u201345.","journal-title":"J Health Serv Res Policy"},{"key":"489_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","volume":"19","author":"J Carpenter","year":"2000","unstructured":"Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19:1141\u201364.","journal-title":"Stat Med"},{"key":"489_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/jphs.12352","volume":"11","author":"J Franchino-Elder","year":"2020","unstructured":"Franchino-Elder J, Gilligan A, Song X, et al. Comparison of healthcare costs among patients with non-valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant. J Pharm Health Serv Res. 2020;11:133\u201340.","journal-title":"J Pharm Health Serv Res"},{"issue":"1","key":"489_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12955-017-0705-x","volume":"15","author":"SL Reynolds","year":"2017","unstructured":"Reynolds SL, Ghate SR, Sheer R, et al. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin. Health Qual Life Outcomes. 2017;15(1):128.","journal-title":"Health Qual Life Outcomes"},{"key":"489_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319\u201330.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00489-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-021-00489-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00489-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T01:22:57Z","timestamp":1641864177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-021-00489-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1007\/s40256-021-00489-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"26 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The MANAGE clinical trial was funded by Boehringer Ingelheim and the Canadian Institutes of Health Research, however no direct funding was allocated for this analysis. The authors had free access to the complete study data and performed all analyses independently of the sponsor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Andre Lamy, Wesley Tong, Rajibul Mian, Jessica Vincent, Wojciech Szczeklik, Bruce M. Biccard, Maria Graza Franzosi, Sadeesh K. Srinathan and Joel Parlow report no conflicts of interest. Emmanuelle Duceppe reports grants from Boehringer Ingelheim, Abbott Diagnostics and Roche Diagnostics, as well as lecture fees from Roche Diagnostics. Philip J. Devereaux reports grants from Boehringer Ingelheim and Canadian Health Research Institutes of Canada during the conduct of the study, and grants from Abbott Diagnostics, Boehringer Ingelheim, Covidien, Octopharma, Philips Healthcare, Roche Diagnostics, and Stryker, all outside the submitted work. Denis Xavier reports grants from Cadila Pharmaceuticals, Boehringer Ingelheim, Sanofi-Aventis, Pfizer, Bristol Myers Squibb, and United Health, all outside the submitted work. Christian S. Meyhoff reports direct and indirect institutional research funding from Ferring Pharmaceuticals, Merck Sharp and Dohme Corp., Radiometer, and Boehringer Ingelheim, as well as lecture fees from Radiometer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material (Data Transparency)"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability (Software Application or Custom Code)"}}]}}